B-intervention	0	9	Tamoxifen
I-intervention	10	14	with
I-intervention	15	17	or
I-intervention	18	25	without
I-intervention	26	32	breast
I-intervention	33	44	irradiation
O	45	47	in
O	48	53	women
O	54	56	50
O	57	62	years
O	63	65	of
O	66	69	age
O	70	72	or
O	73	78	older
O	79	83	with
O	84	89	early
O	90	96	breast
O	97	103	cancer
O	103	104	.

O	105	107	We
O	108	118	determined
O	119	122	the
O	123	129	effect
O	130	132	of
O	133	139	breast
O	140	151	irradiation
O	152	156	plus
O	157	166	tamoxifen
O	167	169	on
O	170	177	disease
O	177	178	-
O	178	182	free
O	183	191	survival
O	192	195	and
O	196	201	local
O	202	209	relapse
O	210	212	in
O	213	218	women
B-age	219	221	50
I-age	222	227	years
O	228	230	of
O	231	234	age
O	235	237	or
O	238	243	older
B-eligibility	244	247	who
I-eligibility	248	251	had
I-eligibility	252	254	T1
I-eligibility	255	257	or
I-eligibility	258	260	T2
I-eligibility	261	265	node
I-eligibility	265	266	-
I-eligibility	266	274	negative
I-eligibility	275	281	breast
I-eligibility	282	288	cancer
O	288	289	.

O	290	297	Between
O	298	306	December
O	307	311	1992
O	312	315	and
O	316	320	June
O	321	325	2000
O	325	326	,
B-total-participants	327	330	769
B-eligibility	331	336	women
I-eligibility	337	341	with
I-eligibility	342	347	early
I-eligibility	348	354	breast
I-eligibility	355	361	cancer
I-eligibility	362	363	(
I-eligibility	363	368	tumor
I-eligibility	369	377	diameter
I-eligibility	377	378	,
I-eligibility	379	380	5
I-eligibility	381	383	cm
I-eligibility	384	386	or
I-eligibility	387	391	less
I-eligibility	391	392	)
O	393	397	were
O	398	406	randomly
O	407	415	assigned
O	416	418	to
O	419	426	receive
O	427	433	breast
O	434	445	irradiation
O	446	450	plus
O	451	460	tamoxifen
O	461	462	(
B-intervention-participants	462	465	386
O	466	471	women
O	471	472	)
O	473	475	or
B-control	476	485	tamoxifen
I-control	486	491	alone
O	492	493	(
B-control-participants	493	496	383
O	497	502	women
O	502	503	)
O	503	504	.

O	505	508	The
O	509	515	median
O	516	522	follow
O	522	523	-
O	523	525	up
O	526	529	was
O	530	531	5
O	531	532	.
O	532	533	6
O	534	539	years
O	539	540	.

O	541	544	The
O	545	549	rate
O	550	552	of
B-outcome	553	558	local
I-outcome	559	566	relapse
I-outcome	567	569	at
I-outcome	570	574	five
I-outcome	575	580	years
O	581	584	was
B-cv-bin-percent	585	586	7
I-cv-bin-percent	586	587	.
I-cv-bin-percent	587	588	7
I-cv-bin-percent	589	596	percent
O	597	599	in
O	600	603	the
O	604	613	tamoxifen
O	614	619	group
O	620	623	and
B-iv-bin-percent	624	625	0
I-iv-bin-percent	625	626	.
I-iv-bin-percent	626	627	6
I-iv-bin-percent	628	635	percent
O	636	638	in
O	639	642	the
O	643	648	group
O	649	654	given
O	655	664	tamoxifen
O	665	669	plus
O	670	681	irradiation
O	682	683	(
O	683	689	hazard
O	690	695	ratio
O	695	696	,
O	697	698	8
O	698	699	.
O	699	700	3
O	700	701	;
O	702	704	95
O	705	712	percent
O	713	723	confidence
O	724	732	interval
O	732	733	,
O	734	735	3
O	735	736	.
O	736	737	3
O	738	740	to
O	741	743	21
O	743	744	.
O	744	745	2
O	745	746	;
O	747	748	P
O	748	749	<
O	749	750	0
O	750	751	.
O	751	754	001
O	754	755	)
O	755	756	,
O	757	761	with
O	762	775	corresponding
B-outcome	776	780	five
I-outcome	780	781	-
I-outcome	781	785	year
I-outcome	786	793	disease
I-outcome	793	794	-
I-outcome	794	798	free
I-outcome	799	807	survival
I-outcome	808	813	rates
O	814	816	of
B-cv-bin-percent	817	819	84
I-cv-bin-percent	820	827	percent
O	828	831	and
B-iv-bin-percent	832	834	91
I-iv-bin-percent	835	842	percent
O	843	844	(
O	844	845	P
O	845	846	=
O	846	847	0
O	847	848	.
O	848	851	004
O	851	852	)
O	852	853	.

O	854	855	A
O	856	863	planned
O	864	872	subgroup
O	873	881	analysis
O	882	884	of
B-total-participants	885	888	611
O	889	894	women
O	895	899	with
O	900	902	T1
O	902	903	,
O	904	912	receptor
O	912	913	-
O	913	921	positive
O	922	928	tumors
O	929	938	indicated
O	939	940	a
O	941	948	benefit
O	949	953	from
O	954	966	radiotherapy
O	967	968	(
B-outcome	968	972	five
I-outcome	972	973	-
I-outcome	973	977	year
I-outcome	978	983	rates
I-outcome	984	986	of
I-outcome	987	992	local
I-outcome	993	1000	relapse
O	1000	1001	,
B-iv-bin-percent	1002	1003	0
I-iv-bin-percent	1003	1004	.
I-iv-bin-percent	1004	1005	4
I-iv-bin-percent	1006	1013	percent
O	1014	1018	with
O	1019	1028	tamoxifen
O	1029	1033	plus
O	1034	1046	radiotherapy
O	1047	1050	and
B-cv-bin-percent	1051	1052	5
I-cv-bin-percent	1052	1053	.
I-cv-bin-percent	1053	1054	9
I-cv-bin-percent	1055	1062	percent
O	1063	1067	with
O	1068	1077	tamoxifen
O	1078	1083	alone
O	1083	1084	;
O	1085	1086	P
O	1086	1087	<
O	1087	1088	0
O	1088	1089	.
O	1089	1092	001
O	1092	1093	)
O	1093	1094	.

O	1095	1102	Overall
O	1102	1103	,
O	1104	1109	there
O	1110	1113	was
O	1114	1115	a
O	1116	1127	significant
O	1128	1138	difference
O	1139	1141	in
O	1142	1145	the
B-outcome	1146	1150	rate
I-outcome	1151	1153	of
I-outcome	1154	1162	axillary
I-outcome	1163	1170	relapse
I-outcome	1171	1173	at
I-outcome	1174	1178	five
I-outcome	1179	1184	years
O	1185	1186	(
B-cv-bin-percent	1186	1187	2
I-cv-bin-percent	1187	1188	.
I-cv-bin-percent	1188	1189	5
I-cv-bin-percent	1190	1197	percent
O	1198	1200	in
O	1201	1204	the
O	1205	1214	tamoxifen
O	1215	1220	group
O	1221	1224	and
B-iv-bin-percent	1225	1226	0
I-iv-bin-percent	1226	1227	.
I-iv-bin-percent	1227	1228	5
I-iv-bin-percent	1229	1236	percent
O	1237	1239	in
O	1240	1243	the
O	1244	1249	group
O	1250	1255	given
O	1256	1265	tamoxifen
O	1266	1270	plus
O	1271	1282	irradiation
O	1282	1283	,
O	1284	1285	P
O	1285	1286	=
O	1286	1287	0
O	1287	1288	.
O	1288	1291	049
O	1291	1292	)
O	1292	1293	,
O	1294	1297	but
O	1298	1300	no
O	1301	1312	significant
O	1313	1323	difference
O	1324	1326	in
O	1327	1330	the
B-outcome	1331	1336	rates
I-outcome	1337	1339	of
I-outcome	1340	1347	distant
I-outcome	1348	1355	relapse
I-outcome	1356	1358	or
I-outcome	1359	1366	overall
I-outcome	1367	1375	survival
O	1375	1376	.

O	1377	1379	As
O	1380	1388	compared
O	1389	1393	with
O	1394	1403	tamoxifen
O	1404	1409	alone
O	1409	1410	,
O	1411	1423	radiotherapy
O	1424	1428	plus
O	1429	1438	tamoxifen
O	1439	1452	significantly
O	1453	1460	reduces
O	1461	1464	the
O	1465	1469	risk
O	1470	1472	of
O	1473	1479	breast
O	1480	1483	and
O	1484	1492	axillary
O	1493	1503	recurrence
O	1504	1509	after
O	1510	1520	lumpectomy
O	1521	1523	in
O	1524	1529	women
O	1530	1534	with
O	1535	1540	small
O	1540	1541	,
O	1542	1546	node
O	1546	1547	-
O	1547	1555	negative
O	1555	1556	,
O	1557	1564	hormone
O	1564	1565	-
O	1565	1573	receptor
O	1573	1574	-
O	1574	1582	positive
O	1583	1589	breast
O	1590	1597	cancers
O	1597	1598	.
